Abbott Sees Absorb Bioresorbable Implant As Stent Market Game Changer
This article was originally published in The Gray Sheet
Executive Summary
Abbott will commence a 2,000-patient clinical trial by year end to support U.S. approval of its Absorb drug-eluting bioresorbable vascular scaffold as an alternative to conventional coronary stents following an initial European debut.
You may also be interested in...
Research In Brief
Oslo breast cancer detection study is good news for Hologic. Abbott's bioresorbable stent trial gets under way. More research briefs.
New Products In Brief
Recent launches and approvals include overseas debuts of Abbott’s Absorb bioabsorbable vascular scaffold and Medtronic’s next-generation CoreValve Evolut transcatheter aortic heart valve.
Firms Tout Data On Next-Gen Stents, But FDA Hurdles May Be Steep
At major cardio meetings this month, stent makers – both start-ups and traditional market leaders – showcased promising data on several next-gen drug-eluting stent systems intended to improve safety, but cardiologists worry that FDA requirements may be too steep.